8th International Wolfram Symposium Presentation Prof Timothy Barrett, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham UK, on behalf of the TREATWOLFRAM investigators (Dr Renuka Dias, Dr Ben Wright (UK), Dr Gema Esteban Bueno (Spain), Prof Wojciech Mlynarski (Poland), Dr Christophe Orssaud, Prof Agathe Roubertie (France)
8th International Wolfram Symposium Presentation Mathias Leinders – Amylyx Pharmaceuticals
Helios – A Phase II Study of Safety and Efficacy of AMX0035 in Wolfram Syndrome
Summary: Update on the clinical trial design of Helios, and the rationale for using AMX0035 as potential treatment for Wolfram Syndrome.
Points noted:
- AMX0035 is a combination therapy of two compounds– TUDCA (tauroursodeoxycholic acid) and sodium phenylbutyrate (PB).
- Approved in the US for ALS, not currently approved in the EU.
- Investigational drug for WS. Received orphan drug status in US.
- Shown to decrease neuronal death, mitigate ER stress and mitochondrial dysfunction.
- Excellent safety and tolerability profile shown in previous studies (Ph III in ALS). Taste issues have been reported previously (AMX0035 = sachet).
- Currently conducting a collaboration with Dr Urano (preclinical and clinical).
- As part of this collaboration, an open label Ph II study has started in US to recruit 12 patients to assess safety (using standard endpoints), tolerability, various measurements (e.g. beta cell function), and exploratory biomarkers.
- Study will monitor C-peptide levels (as a surrogate endpoint) over 24-week period. Patients will therefore need to be relatively healthy to be able to participate (It was noted that not many patients will meet the inclusion criteria required for C-peptide levels). Based on learnings from the dantrolene trial, the target of 12 patients should be achieved.
- The study aims to assess whether there is value in treating WS patients as early as possible and if data are encouraging will expand to larger and longer studies.
- The study protocol includes a 4-hour mixed meal tolerance test (MMTT) (which it was noted is a big ask for patients and researchers). This test was specifically requested by the FDA. If data are encouraging, the aim is to propose to reduce MMTT in a future larger trial.
- If data are encouraging, this will help to spur development in a juvenile programme.
- First patient recruited to this study April 2023 (week prior to the Symposium).
8th International Wolfram Symposium Presentation Prof Gil Leibowitz – President of the Israel Endocrine Society (IES), Hadassah Medical center, the Hebrew University, Jerusalem, Israel.
Pathophysiology and treatment of type 2 Wolfram syndrome.
Abstract: Type 2 Wolfram syndrome results from a missense mutation in the CISD2 gene, encoding NAF-1, which transfers Fe-S clusters from the mitochondria to cytosolic acceptor proteins. The carrier rate of CISD2 missense mutation among the Palestinian population in the Middle East is 1:40, suggesting a founder effect. Type1 and type 2 Wolfram syndrome have common and distinct clinical features, suggesting heterogeneity in disease phenotype and pathophysiology. NAF-1 deficiency leads to increased labile iron accumulation in the mitochondria with subsequent development of mitochondrial dysfunction and oxidative stress, resulting in neurodegeneration and diabetes. Treatment of NAF-1 deficient cells by iron chelation, N-acetylcysteine and GLP-1-RA reduced mitochondrial iron overload and alleviated oxidative stress and mitochondrial dysfunction. I will discuss the therapeutic implications of these findings.
Points noted:
- T2WS is not extremely rare in the Middle east region (compared to WFS1). This is very different from the situation reported elsewhere (e.g. in US – almost all patients have WFS1 mutations rather than CISD2 mutations).
- CISD2 gene mutation (Glutamate – Glutamine, 8 amino acid frameshift with abnormal splicing and stop sequence) generates a protein which is 25% of the size of the native protein that is rapidly degraded. Unrelated families can carry the same mutation.
- Combined GLP-1-RA (e.g. exenatide) and N-acetylcysteine generate increased effects, compared with single treatment (e.g. beta cell protection).
- Better understanding of T2WS has implications for more common forms of Diabetes Mellitus.
- Early intervention is likely to be needed.
- RCTs need broad international collaboration.
- Heterozygous mutations were not studied to date.
About the Snow Foundation
The Snow Foundation is a collective voice for Wolfram syndrome patients, working towards a cure for Wolfram syndrome and developing novel therapies for diabetes, vision loss, hearing loss and neurodegeneration.
Rare Diseases…Common Problems
P.O. Box 50224 Clayton, MO 63105
(402) 694-1354